Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Publishing Clinical Test Results in Medical Publications

<< Previous

Bullboard Posts

Next >>

Comment by Infinityon Sep 07, 2024 9:08am

205 Views

Post# 36213011

RE:RE:Publishing Clinical Test Results in Medical Publications

IRB Appeoval is a required for any clinical study involving Humans. It is needed to protect the rights of patients who participate in clinical studies. I believe IRB approval is a must for FDA to even review and validate the results. There is no way that any study can be conducted without protecting the Patients welfare that FDA will review or approve. I would think New England Journal and The Lancet publishing would be a huge boost fod TLT

<< Previous

Bullboard Posts

Next >>

NTG Clarity Networks' growth story continues with $22M contract